Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 57, Issue 8

Angio-oedema as an unusual tolerable side effect of voriconazole therapy No Access

Abstract

Voriconazole (VRC) has not previously been reported to cause angio-oedema. Here, we report a case of angio-oedema associated with VRC therapy. A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous VRC and developed angio-oedema 10 days after starting therapy. This condition rapidly diminished after administration of intravenous antihistaminics and did not necessitate cessation of VRC treatment. The treatment was continued for 6 months without recurrence of the symptoms. After 18 months, the patient was in good health. To our knowledge, this is the first report of an angio-oedema associated with VRC.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): AmB, amphotericin B , CRP, C-reactive protein , ESR, erythrocyte sedimentation rate , IA, invasive aspergillosis and VRC, voriconazole
SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47299-0
2008-08-01
2025-03-19
Loading full text...

Full text loading...

References

  1. Ally R., Schurmann D., Kreisel W., Carois G., Aguirrebengoa K., Dupont B., Hodges M., Troke P., Romero A. J. theEsophageal Candidiasis Study Group 2001; A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33:1447–1454 [CrossRef]
     [Google Scholar]
  2. Bates D. W., Su L., Yu D. T., Chertow G. M., Seger D. L., Gomes D. R., Dasbach E. J., Platt R. 2001; Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686–693 [CrossRef]
     [Google Scholar]
  3. Denning D. W. 1998; Invasive aspergillosis. Clin Infect Dis 26:781–803 [CrossRef]
     [Google Scholar]
  4. Denning D. W., Griffiths C. E. 2001; Mucocutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 26:648–653 [CrossRef]
     [Google Scholar]
  5. Denning D. W., Stevens D. A. 1990; Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 12:1147–1201 [CrossRef]
     [Google Scholar]
  6. Denning D. W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., Haas A., Ruhnke M., Lode H. 2002; Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571 [CrossRef]
     [Google Scholar]
  7. Ghannoum M. A., Kuhn D. M. 2002; Voriconazole – better chances for patients with invasive mycoses. Eur J Med Res 7:242–256
     [Google Scholar]
  8. Gunsilius E., Lass-Florl C., Mur E., Gabl C., Gastl G., Petzer A. L. 1999; Aspergillus osteoarthritis in acute lymphoblastic leukemia. Ann Hematol 78:529–530 [CrossRef]
     [Google Scholar]
  9. Herbrecht R., Denning D. W., Patterson T. F., Bennett J. E., Greene R. E., Oestmann J. W., Kern W. V., Marr K. A., Ribaud P. other authors 2002; Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415 [CrossRef]
     [Google Scholar]
  10. Johnson L. B., Kauffman C. A. 2003; Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630–637 [CrossRef]
     [Google Scholar]
  11. Kirkpatrick W. R., McAtee R. K., Fothergill A. W., Rinaldi M. G., Patterson T. E. 2000; Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 44:2865–2868 [CrossRef]
     [Google Scholar]
  12. Kohli R., Hadley S. 2005; Fungal arthritis and osteomyelitis. Infect Dis Clin North Am 19:831–851 [CrossRef]
     [Google Scholar]
  13. Lazarus H. M., Blumer J. L., Yanovicjh S., Schlamm H., Romero A. 2002; Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 42:395–402 [CrossRef]
     [Google Scholar]
  14. Mouas H., Lutsar I., Dupont B., Fain O., Herbrecht R., Lescure F. X., Lortholary O. theBone Invasive Aspergillosis Study Group 2005; Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 40:1141–1147 [CrossRef]
     [Google Scholar]
  15. Murphy M., Bernard E. M., Ishimaru T., Armstrong D. 1997; Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 41:696–698
     [Google Scholar]
  16. Perez-Gomez A., Prieto A., Torresano M., Díez E., Mulero J., Labiano I., Andreu J. L. 1998; Role of the new azoles in the treatment of fungal osteoarticular infections. Semin Arthritis Rheum 27:226–244 [CrossRef]
     [Google Scholar]
  17. Perfect J. R., Marr K. A., Walsh T. J., Greenberg R. N., DuPont B., de la Torre-Cisneros J., Just-Nübling G., Schlamm H. T., Lutsar I. other authors 2003; Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin Infect Dis 36:1122–1131 [CrossRef]
     [Google Scholar]
  18. Pfaller M. A., Messer S. A., Hollis R. J., Jones R. N. 2002; Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillence Program, 2000. Antimicrob Agents Chemother 461032–1037 [CrossRef]
     [Google Scholar]
  19. Purkins L., Wood N., Ghahramani P., Greenhalgh K., Allen M. J., Kleinermans D. 2002; Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546–2553 [CrossRef]
     [Google Scholar]
  20. Stevens D. A., Kan V. L., Judson M. A., Morrison V. A., Dummer S., Denning D. W., Bennett J. E., Walsh T. J., Patterson T. F., Pankey G. A. 2000; Practice guidelines for diseases caused by Aspergillus . Clin Infect Dis 30:696–709 [CrossRef]
     [Google Scholar]
  21. Stratov I., Korman T. M., Johnson P. D. 2003; Management of Aspergillus osteomyelitis: report of failure of liposomal amphotericin B and response to voriconazole in an immunocompetent host and literature review. Eur J Clin Microbiol Infect Dis 22:277–283
     [Google Scholar]
  22. Walsh T. J., Lutsar I., Driscoll T., Dupont B., Roden M., Ghahramani P., Hodges M., Groll A. H., Perfect J. R. 2002a; Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21:240–248 [CrossRef]
     [Google Scholar]
  23. Walsh T. J., Pappas P., Winston D. J., Lazarus H. M., Petersen F., Raffalli J., Yanovich S., Stiff P., Greenberg R. & other authors (2002b). Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234 [CrossRef]
     [Google Scholar]
  24. Wingard J. R., Kubilis P., Lee L., Yee G., White M., Walshe L., Bowden R., Anaissie E., Hiemenz J., Lister J. 1999; Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29:1402–1407 [CrossRef]
     [Google Scholar]
  25. Winkelstein J. A., Marino M. C., Johnson R. B., Boyle J., Curnutte J. Jr, Gallin J. I., Malech H. L., Holland S. M., Ochs H. other authors 2000; Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 79:155–169 [CrossRef]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.47299-0
Loading

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error